Bugesic - Tablet Buprenorphine - 200mcg 1 Tablet(s) / Tablet Beximco Pharmaceuticals Ltd. Introduction: Bugesic is used to treat moderate to severe pain and drug dependence/addiction to opioids. It helps to prevent withdrawal symptoms that may be caused due to withdrawal of other opioids. Bugesic is only prescribed to individuals who are at least 16 years of age or above. It may be habit forming and should be taken only as directed by your doctor. The medicine may be a part of your treatment which could include receiving social and psychological support. It can be taken with or without food. You should continue taking this medicine regularly until the doctor tells you it is... Uses of Bugesic: Opioid (Morphine) dependence Side effects of Bugesic: WeaknessDrug withdrawal syndrome How to use Bugesic: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Bugesic may be taken with or without food, but it is better to take it at a fixed time. How Bugesic works: Bugesic is a opioid partial agonist. It prevents withdrawal symptoms in patients who stop taking opioid drugs by producing similar effects to these drugs. Indication: Pain, Anaesthesia, Opioid dependence Administration: V Preparation Solution: Dilute to final concentration of 15 mcg/mL in D5W, D5/NS, NS, or LR Administer via controlled infusion device IV/IM Administration Administer by deep IM injection, by slow IV injection over >2 minutes, or by continuous IV infusion Also may be given by epidural injection at concentration of 6-30 mcg/mL Adult Dose: Adult: Sublingual Moderate to severe pain 200-400 mcg 6-8 hrly. IV Perioperative analgesia 300-450 mcg via slow inj. IV/IM Moderate to severe pain 300-600 mcg 6-8 hrly. IM Anesth premed 300 mcg. Elderly: Moderate-to-Severe Pain 0.15 mg IV/IM q6hr; for IV, administered slowly over 2 minutes Child Dose: Moderate-to-Severe Pain 12 years: As in adults Contraindication: Acute alcoholism; convulsive disorders; head injuries; increased intracranial pressure; comatose patients; resp depression and obstructive airway disease; patients on established opioid agonists. Mode of Action: Buprenorphine exerts its analgesic effect by binding to the mu-opioid receptors in the CNS. It has a longer duration of analgesic action than morphine. Its partial agonist activity gives it a low level of physical dependence. Buprenorphine and morphine show similar dose-related resp depressant effect. Precaution: Hepatic or renal disease; pregnancy, lactation; hypothyroidism; adrenocortical insufficiency; asthma; prostatic hyperplasia; shock; hypotension; inflammatory or obstructive bowel disorders; myasthaenia gravis; infants/neonates. Reduce dose in elderly and debilitated patients. May precipitate withdrawal symptoms in narcotic addicts. Lactation: Drug enters breast milk; use not recommended Side Effect: >10% Sedation (2/3 of patients) 1-10% Dizziness,Headache,Hypotension,Hypoventilation,Miosis,Nausea,Sweating,Vertigo,Vomiting <1% Abdominal cramps,Amblyopia,Apnea,Blurred vision,Bradycardia,Coma,Confusion,Conjunctivitis,Constipation,Cyanosis,Depersonalization,Diplopia,Dreaming,Dry mouth,Dyspepsia,Dyspnea,Electrocardiographic (ECG) abnormalities,Euphoria,Fatigue,Flatulence,Hallucinations,Hypertension,Injection-site reactions,Malaise,Mental depression,Mydriasis,Nervousness,Paresthesia,Pruritus,Psychosis,Respiratory depression,Slurred speech,Tachycardia,Urticaria Pregnancy Category Note: Pregnancy Data in pregnancy are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure; observational studies reported on congenital malformations among exposed pregnancies, but were also not designed appropriately to assess risk of congenital malformations specifically due to drug exposure Dosage adjustments of buprenorphine may be required during pregnancy, even if patient was maintained on stable dose prior to pregnancy; withdrawal signs and symptoms should be monitored closely and the dose adjusted as necessary Fetal/neonatal adverse reactions Neonatal opioid withdrawal syndrome may occur in newborn infants of mothers who are receiving... Interaction: Plasma-buprenorphine concentrations may be affected when co-administered with drugs that induce or inhibit cytochrome P450 isoenzyme CYP3A4. Enhanced depressant effects with other CNS depressants e.g. alcohol, anaesthetics, anxiolytics, hypnotics, TCAs and antipsychotics. Potentially Fatal: Diazepam may produce resp and cardiac collapse.